High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.

Boots, Johannes M M; Quax, Rogier A M

Boots, Johannes M M; Quax, Rogier A M.

Affiliation

Boots JMM; Department of Internal Medicine, Maasstad Hospital, Maasstadweg 21, 3079 DZ, Rotterdam, The Netherlands. BootsJ@maasstadziekenhuis.nl.
Quax RAM; Department of Internal Medicine, Maasstad Hospital, Maasstadweg 21, 3079 DZ, Rotterdam, The Netherlands.

Drug Saf ; 45(10): 1019-1036, 2022 10.

Article in En | MEDLINE | ID: mdl-36068430

Subject(s)

Hypophosphatemia; Iron; Disaccharides; Ferric Compounds; Hormones; Humans; Hypophosphatemia/chemically induced; Maltose/analogs & derivatives; Phosphates/adverse effects; Prospective Studies; Risk Assessment

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Hypophosphatemia / Iron Type of study: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Language: En Journal: Drug Saf Year: 2022 Type: Article Affiliation country: Netherlands

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google